Loading clinical trials...
Loading clinical trials...
Clinical Study of Fibroblast Activating Protein Inhibitor (FAPI) -Mediated 18F Targeted to Evaluate Inflammation and Fibrosis in Renal Diseases
The goal of this observational study is to explore the feasibility of using 18F-labeled FAP molecular probe for PET/CT imaging (18F-FAPI PET/CT) to accurately evaluate inflammation and fibrosis in renal diseases. The main questions it aims to answer are: * Can 18F-FAPI PET/CT accurately evaluate the inflammation and fibrosis of kidney disease? * What is the value of 18F-FAPI PET/CT as a non-invasive assessment of inflammation and fibrosis in kidney disease? Participants will receive \[18F\]AlF-NOTA-FAPI-04 PET/CT and renal aspiration biopsy.
Age
10 - 80 years
Sex
ALL
Healthy Volunteers
No
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Start Date
February 1, 2023
Primary Completion Date
August 30, 2024
Completion Date
November 30, 2024
Last Updated
January 24, 2024
30
ESTIMATED participants
[18F]AlF-NOTA-FAPI-04 PET/CT examination
DEVICE
Renal puncture biopsy
PROCEDURE
Lead Sponsor
Sichuan Provincial People's Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions